Novo Nordisk today announced the launch of Wegovy® pill (semaglutide tablets) in the United Arab Emirates (UAE), the first country outside the United States to make the Wegovy® pill available to people living with obesity. The launch marks an important step in Novo Nordisk’s ambition to expand access to innovative obesity treatments and broaden treatment options for people living with obesity around the world. “I am thrilled that Wegovy® pill is now available in the UAE,” said Emil Kongshøj Larsen, executive vice president, International Operations at Novo Nordisk. “This launch ...